erlotinib hydrochloride has been researched along with atractylenolide i in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (atractylenolide i) | Trials (atractylenolide i) | Recent Studies (post-2010) (atractylenolide i) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 85 | 0 | 69 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hann, SS; Huang, HD; Tang, Q; Wu, JJ; Xiao, Q; Xie, J; Yang, XB; Zheng, F | 1 |
1 other study(ies) available for erlotinib hydrochloride and atractylenolide i
| Article | Year |
|---|---|
Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lactones; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering; Sesquiterpenes | 2018 |